Roche Holding AG plans to test whether an experimental medicine can prevent Alzheimer’s disease symptoms in high-risk people, ...

(Reuters) -Swiss drugmaker Roche Holding plans to test whether an experimental medicine can prevent Alzheimer's disease ...

A direct-to-consumer program for its drugs could bring down higher U.S. drug prices while cutting out pharmacy benefit ...

Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken ...

In a Phase Ib/IIa trial, 91% of patients receiving the highest dose of trontinemab were amyloid negative after seven months ...

Despite a new setback for Elevidys in Europe, Roche—which markets Sarepta’s gene therapy outside the U.S.—remains committed ...

The U.S. Food and Drug Administration said on Friday it was investigating the death of an eight-year-old boy who received ...

The drugmaker’s sales were up 7% at constant currency from the same period last year.

Roche is following its partner Sarepta and halting shipments of the Duchenne gene therapy Elevidys in some countries, amid ...

Roche had bid $91 a share in what it said was its best and final offer. But it would eventually relent and win by bidding $114.50 a share, almost $10 more than its rival, at the end of the day.

Swiss drugmaker Roche Holding plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease ...